SCHEMBL29649487

SCHEMBL29649487

CCCCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 1/20 0.54
SLC6A5 Q9Y345 1/20 0.54
EPHX2 P34913 6/20 0.52
KDM4E B2RXH2 1/20 0.52
CASP2 P42575 1/20 0.50
PLA2G4A P47712 1/20 0.50
NAAA Q02083 1/20 0.47
PLA2G2A P14555 1/20 0.46
AKR1B1 P15121 1/20 0.46
FAAH O00519 3/20 0.45
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.45
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901240 0.90 CASP2 (0.58) MEN1MAPTKMT2ASLC6A5EPHX2
SCHEMBL15503356 0.88 EPHX2 (0.64) MEN1MAPTKMT2ASLC6A5EPHX2
SCHEMBL29649591 0.87 SMN1; SMN2 (0.50) MEN1MAPTKMT2ASLC6A5EPHX2
SCHEMBL11912076 0.87 CASP2 (0.66) EPHX2CASP2NAAAFAAHTSHR
SCHEMBL11226598 0.86 EPHX2 (0.66) MEN1MAPTKMT2ASLC6A5EPHX2
SCHEMBL8251628 0.85 CASP2 (0.63) EPHX2CASP2NAAAFAAHCNR1
SCHEMBL19977979 0.85 CASP2 (0.53) CASP2NAAAFAAHTSHRRECQL
SCHEMBL25574266 0.85 CASP2 (0.63) EPHX2CASP2NAAAFAAHTSHR
SCHEMBL22562632 0.84 EPHX2 (0.60) MEN1MAPTKMT2ASLC6A5EPHX2
SCHEMBL14118056 0.84 EPHX2 (0.60) MEN1MAPTKMT2ASLC6A5EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4237008-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF Elucida Oncology, Inc. (US) 2023-09-06 EP disclosed
WO-2022093800-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 WO disclosed